Related Experiment Videos
Potent, low molecular weight thrombin receptor antagonists
S Chackalamannil1, D Doller, K Eagen
1Schering-Plough Research Institute, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, USA. samuel.chackalamannil@spcorp.com
Bioorganic & Medicinal Chemistry Letters
|October 13, 2001
Summary
Researchers identified potent benzimidazole derivatives as protease-activated receptor-1 (PAR-1) antagonists. Compound 1h demonstrated significant inhibitory activity, highlighting its potential in therapeutic applications.
Area of Science:
- Medicinal Chemistry
- Biochemistry
- Pharmacology
Background:
- Protease-activated receptor-1 (PAR-1) plays a critical role in thrombosis and inflammation.
- Developing selective PAR-1 antagonists is a key therapeutic strategy for cardiovascular diseases.
- Benzimidazole scaffolds are known for their diverse biological activities.
Purpose of the Study:
- To synthesize and evaluate novel benzimidazole derivatives as potential PAR-1 antagonists.
- To identify specific structural features that confer potent PAR-1 inhibitory activity.
Main Methods:
- Synthesis of a library of benzimidazole derivatives.
- In vitro biochemical assays to measure PAR-1 antagonism.
- Determination of inhibitory concentrations (IC50) for active compounds.
Main Results:
- Several benzimidazole derivatives exhibited significant PAR-1 antagonist activity.
- Compound 1h demonstrated potent inhibition with an IC50 value of 33 nM.
- Structure-activity relationship analysis provided insights into key pharmacophoric elements.
Conclusions:
- Benzimidazole derivatives represent a promising class of PAR-1 antagonists.
- Compound 1h is a lead candidate for further preclinical development.
- Targeting PAR-1 with these novel compounds may offer new therapeutic avenues.